Parkinson's disease (PD) is a neurodegenerative disease characterized pathologically by α-
synuclein (α-syn) aggregation. In PD, the current mainstay of symptomatic treatment is …

Parkinson's disease (PD) is one of the most prevalent neurodegenerative disease
displaying negative impacts on both the health and social ability of patients and …

Adenosine A2A receptors (A2ARs) have attracted considerable attention as an important
molecular target for the design of Parkinson's disease (PD) therapeutic compounds. Here …

Adenosine receptors are G protein-coupled receptors (GPCRs) that mediate the
physiological functions of adenosine. In the central nervous system adenosine A2A …

In modern societies, with an increase in the older population, age-related
neurodegenerative diseases have progressively become greater socioeconomic burdens …

Parkinson's disease (PD) is a neurodegenerative disease with significant unmet medical
needs. The current dopamine-centered treatments aim to restore motor functions of patients …

Although there is no cure for Parkinson's disease (PD), there are several classes of
medications with various mechanisms of action that can help improve the functionality of …

The quest for a non-dopaminergic approach to treating Parkinson's disease (PD) has been
quietly progressing over the past several decades, and is now finding its momentum. Here …

Neuroinflammation is one of the driving forces of progressive neurodegeneration in
Parkinson's disease (PD). The metabolomics approach has been proved highly useful in …

The motor symptoms of Parkinson's disease (PD) are primarily due to the degeneration of
the dopaminergic neurons in the nigrostriatal pathway. However, several other brain areas …